In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Neovasc grosses $32.8mm via private placement

Executive Summary

Neovasc Inc. (cardiovascular devices) completed a private placement of $32.8mm aggregate principal amount of senior secured convertible notes and Series E warrants to purchase one common share. The 18-month notes will be issued with an original issue price of $850 per $1,000 principal amount and carry an interest rate of 0.0% per year (increasing to 15% upon an event of default). The company concurrently netted $35.2mm through a follow-on offering and will use the proceeds from both financings to fully fund the balance of the awards granted in the litigation with CardiAQ Valve related to its Tiara technology, and to help fund the ongoing Tiara transcatheter device trial.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Convertible Debt
    • Private Placement

Related Companies

UsernamePublicRestriction

Register